Overview

Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Status:
Active, not recruiting

Trial end date:
2024-03-21

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 4 to 16 year old participants.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Vaccines